Morningstar® Stock Report™

Boston Scientific Corp BSX

Último Precio
73.26
Cambio del día
0.35|0.48%

a 25/04/2024
18:14:31 EDT | USD  Retraso mínimo: 15 minutos

Bid/OffersRango del DíaVolumen90d Ave VolCapitalización
73.27 - 73.8172.91 - 73.648,171,3926,514,350107.70Bil
Último Cierre52 Week RangeP/UDividendo %ISIN
72.9148.35 - 74.3968.14-US1011371077

Cotización Boston Scientific Corp

Mr. Lee Davidson, Head of Quantitative Research
The conduct of Morningstar's analysts is governed by Morningstar's Code of Ethics, Securities Trading and Disclosure Policy, and Investment Research Integrity Policy. For information regarding conflicts of interest, please click here.
Fair Value is derived from a detailed projection of a company’s future cash flows. Analysts create custom industry and company assumptions to feed income statement, balance sheet, and capital investment assumptions into a proprietary discounted cash flow modeling template. Scenario analysis, in-depth competitive advantage analysis, and a variety of other analytical tools are used to augment the discounted cash flow process. Combining analysts’ financial forecasts with the firm’s economic moat helps us assess how long returns on invested capital are likely to exceed the firm’s cost of capital. Because we are modeling free cash flow to the firm—representing cash available to provide a return to all capital providers—we discount future cash flows using the weighted average of the costs of equity, debt, and preferred stock (and any other funding sources), using expected future proportionate long-term, market-value weights. If our base-case assumptions are true the market price will converge on our fair value estimate over time, generally within three years. Investments in securities are subject to market and other risks. Past performance of a security may or may not be sustained in future and is no indication of future performance. For detail information about the Qualitative Fair Value, please click here.
Cuentas Financieras
202120222023
Más...
Cuenta de Resultados
Ingresos11,888.0012,682.0014,240.00
Resultado Operativo1,824.002,033.002,417.00
Resultado Neto1,041.00698.001,593.00
Beneficio Básico por Acción0.690.451.08
Num Medio Acciones diluidas en circulación1,4341,4401,464
Balance
Activo Corriente6,317.005,760.006,514.00
Activos no corrientes25,911.0026,710.0028,621.00
Total Activo 32,229.0032,469.0035,136.00
Pasivo corriente4,274.003,803.004,933.00
Total Pasivo---
Capital Total16,623.0017,574.0019,281.00
Flujo de Caja
Flujo de caja operativo1,870.001,526.002,503.00
Inversiones de Capital-554.00-612.00-800.00
Flujo de Caja Libre1,316.00914.001,703.00

En millones, excepto "EPS básico". La moneda es USD.

Perfil de la compañía

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

Sector

Atención sanitaria

Industria

Dispositivos Médicos

Estilo de acciones

Grande-Crecim

Fin Ejercicio Fiscal

diciembre

Empleados

48,000
Principales Características
Más...
Precio/Beneficio 12 m67.51
Precio/Valor contable5.56
Precio/Ventas TTM7.49
Crec Ingresos (media 3 a)12.83
Crec BPA (media 3 a)-
Margen operativo16.97
Margen neto11.19
ROE 12 m8.52
Deuda/Fondos propios0.46
Dividendos
AntÚltimo
Fecha declaradat.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Pagadot.b.c.t.b.c.
Cantidad0.000.00
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures